GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first ...

GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...

GSK (GSK) announced that the National Medical Products Administration, NMPA, of China has accepted for review a new drug application, NDA, for ...

The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed ...